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P
rogress in biomedical research is documented in
journals after peer review, a process with ﬂaws
but the best we have. Once an article is pub-
lished, in general it faces three fates. Most com-
monly, after some measure of initial interest, it quietly
slips into obscurity, only occasionally to resurface if cited
by a vigilant successor who recognizes the prior contribu-
tion to a once again advancing ﬁeld. A quick glance
through a copy of any major medical journal published
50 years ago is a humbling experience for any active
scientist. Many of the conﬁdently stated conclusions, with
hindsight, were quite simply wrong. How many of our
conclusions today will seem mildly amusing to a reader 50
years from now? Occasionally, an article makes a tremen-
dously important contribution that advances a ﬁeld and is
widely cited, becoming a so-called citation classic with
little controversy. Reading such a paper that is 50 years
old can also be a humbling experience. How did the
authors have such insight from what we now consider an
incomplete dataset obtained by insensitive and nonspe-
ciﬁc methods compared with those available to us now?
It was clear to the editorial team at Diabetologia that an
article recently submitted to that journal was one that fell
into a third category (1)—an article that is likely to incite
immediate controversy. Typically, such an article, once
published after peer review, then stands or falls as a result
of wider scrutiny by scientiﬁc peers. At ﬁrst sight, it would
seem that the early controversy is harmless enough if the
authors are willing to stand the heat in the kitchen.
However, there is an important exception to this in
biomedical research: if the conclusion of the paper might
alter clinical practice in such a way that patients can be
harmed or contains information that might lead to unnec-
essary concern for patients if the information reaches the
general media.
When an article that reported an increased incidence of
cancer in people using insulin glargine (1) was submitted
to Diabetologia, the editors took extraordinary steps. Not
only was the article subject to the usual peer review, but
before publishing the study, the editors solicited addi-
tional studies from investigators with epidemiological
databases from several nations (2,3,4). Is such expediency
by editors of a journal typical? I think we have to agree
that the answer is no. The resulting studies were then
published together in a recent edition of Diabetologia
along with a cautiously worded editorial and a statement
from the journal’s host organization (5), the European
Association for the Study of Diabetes. The accompanying
editorial was careful to point out that the assembled data,
while raising some concern whether insulin glargine might
increase the risk of cancer, were not deﬁnitive and indi-
cated the need for additional studies. The purpose of this
editorial is not to join the ongoing debate about the
increment in risk, if any, of the use of insulin glargine to
treat diabetes. As the editors of Diabetologia conclude, the
debate can only be resolved by further studies, which may
or may not be performed.
Rather, the purpose of this editorial is to serve counter-
point to some quite harshly worded statements published
rapidly after the Diabetologia articles and the accompany-
ing editorial. “Insulin Glargine and Malignancy: An Unwar-
ranted Alarm” is the title of a comment published in The
Lancet (6). “Insulin Glargine and Cancer—An Unsubstan-
tiated Allegation” is the title of an editorial in Diabetes
Technology & Therapeutics, under the heading of which
the authors confer themselves high honor by citing
Charles Darwin, “to kill an error is as good a service as,
and sometimes even better than, the establishing of a new
truth or fact” (7). Based on the ﬂurry of correspondence
and phone calls coming to those of us who prescribe
insulin, the most apparent “alarm” following the publica-
tion of the articles in Diabetologia was that of the com-
pany that sells insulin glargine. And with due respect to
Charles Darwin, we are not sure he would yet agree that an
error has been perpetrated given the cautious conclusions
of the Diabetologia editorial. Practicing physicians were
for the most part content with the measured statements
that were released by the national organizations, and
patients do not seem unduly alarmed.
In contrast to some of the rather strident editorial
comments published in response to the articles and the
editorial in Diabetologia,w ea tDiabetes offer our congrat-
ulations to the editorial team at Diabetologia for taking
such extraordinary measures to obtain the additional
studies and to write a carefully balanced editorial to go
with the ﬁrst submission that they received. The assem-
bled articles have drawn attention to the long-known but
little-investigated link between type 2 diabetes and cancer
(5). It is now much better appreciated that metformin
therapy decreases cancer risk (4,8,9). Based on the assem-
bled data, use of higher dose of insulin therapy may
accelerate the growth of existing cancers (5). As the
editorial in Diabetologia points out, the question whether
long-acting insulin analogs have an additional effect on
cancer risk remains unresolved but, based on the available
evidence, deserves further study.
Taking the 50-year perspective alluded to above, we are
conﬁdent that the editorial accompanying these articles in
Diabetologia will age well. Moreover, it is surely the
responsibility of the scientiﬁc community and journal
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tended adverse consequences of an available therapy, as
unpalatable as such concerns may be for those who
market the product.
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